A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro

Melanie Adler,*† Susanne Ramm,* Marc Hafner,* Jeremy L. Muhlich,* Esther Maria Gottwald,† Elijah Weber,‡ Alenka Jaklic,‡ Amrendra Kumar Ajay,† Daniel Svoboda,§ Scott Auerbach,‖ Edward J. Kelly,‡ Jonathan Himmelfarb,¶ and Vishal S. Vaidya*†**

*Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, Massachusetts; †Renal Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; ‡Department of Pharmaceutics, University of Washington, Seattle, Washington; §Social and Scientific Systems, Durham, North Carolina; ‖National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina; †Kidney Research Institute, Department of Medicine, University of Washington, Seattle, Washington; and ‡Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

ABSTRACT
Nephrotoxicity due to drugs and environmental chemicals accounts for significant patient mortality and morbidity, but there is no high throughput in vitro method for predictive nephrotoxicity assessment. We show that primary human proximal tubular epithelial cells (HPTECs) possess characteristics of differentiated epithelial cells rendering them desirable to use in such in vitro systems. To identify a reliable biomarker of nephrotoxicity, we conducted multiplexed gene expression profiling of HPTECs after exposure to six different concentrations of nine human nephrotoxicants. Only overexpression of the gene encoding heme oxygenase-1 (HO-1) significantly correlated with increasing dose for six of the compounds, and significant HO-1 protein deregulation was confirmed with each of the nine nephrotoxicants. Translatability of HO-1 increase across species and platforms was demonstrated by computationally mining two large rat toxicogenomic databases for kidney tubular toxicity and by observing a significant increase in HO-1 after toxicity using an ex vivo three-dimensional microphysiologic system (kidney-on-a-chip). The predictive potential of HO-1 was tested using an additional panel of 39 mechanistically distinct nephrotoxic compounds. Although HO-1 performed better (area under the curve receiver-operator characteristic curve [AUC-ROC]=0.89) than traditional endpoints of cell viability (AUC-ROC for ATP=0.78; AUC-ROC for cell count=0.88), the combination of HO-1 and cell count further improved the predictive ability (AUC-ROC=0.92). We also developed and optimized a homogenous time-resolved fluorescence assay to allow high throughput quantitative screening of nephrotoxic compounds using HO-1 as a sensitive biomarker. This cell-based approach may facilitate rapid assessment of potential nephrotoxic therapeutics and environmental chemicals.


Drugs and environmental chemicals, such as aminoglycoside antibiotics, analgesics, chemotherapeutic agents, and heavy metals, as well as endemic toxins like aristolochic acid are a common cause of AKI or CKD.1,2 Current approaches to conduct safety and risk assessment of compounds rely predominantly on animal studies, and these results are extrapolated to dose effects in humans despite knowledge that the typical responses of animal models and humans can differ greatly.3 The lack of adequate models to accurately predict human toxicity contributes to an underestimation of the kidney toxic potential of new therapeutic candidates, which also explains why nephrotoxic effects in patients are often only detected during late phase

Received January 15, 2015. Accepted June 16, 2015.
M.A. and S.R. contributed equally to this work.
Published online ahead of print. Publication date available at www.jasn.org.
Correspondence: Dr. Vishal S. Vaidya, Harvard Institutes of Medicine, Rm 562, 77 Avenue Louis Pasteur, Boston, MA 02115. Email: vaidya@bwh.harvard.edu
Copyright © 2015 by the American Society of Nephrology
clinical trials or, in some cases, after regulatory approval. Additionally, few registered chemicals have been fully assessed for their potential to cause kidney toxicity, while the number of new chemicals being synthesized annually for use in consumer products is increasing rapidly. Given the societal burden of kidney disease and the insensitivity of current methods to detect it, there is an urgent need to develop quantitative, sensitive, and robust methods for predictive assessment of human kidney toxicity.

Advancing early-stage safety assessment of large numbers of compounds, a paradigm shift in toxicology initiated by the Tox21 program, demands moving away from whole animal testing toward less expensive and higher throughput cell-based assays. Currently, there is no in vitro method that can be used in a high throughput manner to identify kidney toxic agents early in the process before reaching humans. Immortalized kidney epithelial cell lines, derived from human kidney (HK-2), pig kidney (LLC-PK1), or dog kidney (MDCK), frequently used for nephrotoxicity studies, do not fully express all the differentiated functions found in their in vivo counterparts due to loss of polar architecture and changes in drug transporter expression. Primary proximal tubular epithelial cells of human origin, being the predominant target of most toxicants in the kidney, are characterized by polarity and junctional assembly of epithelia, brush border enzyme activity, and metabolic and transport capacity. Among the currently available two-dimensional (2D) models, they are the model that comes closest to the ideal with respect to kidney physiology and toxicology studies.

The primary objective of this study was to develop a cell-based approach for safety screening of kidney toxic compounds. Specifically the aims were: to evaluate the structural and functional characteristics of human primary tubular epithelial cells; to identify a translational biomarker that, either alone or in combination with known markers, would enable prediction of risk for kidney toxicity across species and platforms; and to develop a time resolved fluorescence resonance energy transfer (FRET) assay for measuring the biomarker, which would allow improved quantitation of kidney toxicity in a high throughput manner.

RESULTS

Structural and Functional Characterization of Primary HPTECs as a Suitable In Vitro Model for Screening Kidney Toxicity

We structurally and functionally characterized human proximal tubular epithelial cells (HPTECs) to determine whether they exhibit features of a differentiated kidney proximal tubular epithelium. HPTECs expressed zonula occludens 1, cytokeratin 18 (CK18), E-cadherin, and N-cadherin, indicating tight junction assembly and cell polarity (Figure 1A). The cells also showed a consistent expression of kidney-specific cadherin, as well as a wide range of efflux and influx transporters, such as megalin, aquaporin-1, multidrug resistance protein 2 (MRP2), P-glycoprotein (MDR1), and organic cation transporter 2 across different passages and cultivation periods (Figure 1B). These findings correlated well with the RNA expression pattern observed in human kidney (Figure 1B). In contrast, aquaporin-1 and kidney-specific cadherin mRNA were not detected in HK-2 cells, which are immortalized human proximal tubular cells. The development of HPTECs to polarized confluent monolayers on collagen IV coated transwells was evaluated by an increase in transepithelial electrical resistance over 7 d of culture (Figure 1C). Confluent monolayers of HPTECs in well plates also formed typical domes, indicative of transepithelial solute transport (data not shown). Sucrose transport was demonstrated to be active across cell monolayers grown on transwell filters for 7 d as well as in monolayers cultured in well plates (Figure 1D). Based on a significant cellular efflux of rhodamine 123, a fluorescent MDR1 substrate, we showed that the transporter is functional in HPTECs (Figure 1E). Time and dose-dependent glucose transport (Figure 1F, left panel) could be attributed to Na+-dependent (SGLT) and Na+-independent (GLUT) transport processes (Figure 1F, right panel). Exposure of cells to various concentrations of cadmium chloride (CdCl2) for up to 24 h increased γ-glutamyl-transferase activity and elevated levels of cellular glutathione in a time and dose-dependent manner (Figure 1G). Finally, activity and functionality of mitochondria in HPTECs were demonstrated after treatment with different inhibitors of oxidative phosphorylation, causing either loss of mitochondrial membrane potential (MMP) without production of reactive oxygen species (ROS) (carbonyl cyanide m-chlorophenyl hydrazone), or pronounced production of ROS without affecting the MMP (oligomycin A) (Figure 1H). These data suggest that HPTECs represent a suitable in vitro model as they retain many of the phenotypic as well as functional characteristics of the human proximal tubule.

Identification of HO-1 as a Biomarker for In Vitro Kidney Toxicity

In order to identify a potential biomarker that allows identification of kidney toxic compounds before changes in cell morphology or detectable loss of viability occur, we conducted gene expression profiling by measuring 1000 landmark genes characteristic of the variability of the transcriptome. HPTECs were cultured for 3 d in collagen-coated multwell plates until confluence before treatment with a discovery panel (Supplemental Table 1) consisting of nine structurally and mechanistically distinct kidney toxic compounds (cisplatin, cyclosporin A (CsA), cadmium chloride (CdCl2), aristolochic acid (AA), gentamicin, FK-506, tobramycin, doxorubicin, ochratoxin A) versus the nontoxic compound (carboplatin) at concentrations ranging from 1.6 μM to 20 mM over four different time points (3, 6, 12 and 24 h). Supplemental Figure 1 shows compound-induced changes in phenotype of the cells and loss of cell viability based on ATP concentrations. The
1000 selected transcripts were measured for each sample in a single well of a 384-well plate using Luminex based technology. For each gene and drug, we calculated the correlation between the dose and the fold change in gene expression at each time point and calculated an empirical \( P \) value (Figure 2, A and B, see the methods section for details). Based on all gene-drug pairs, we found that HMOX1 (HO-1, heme oxygenase-1) was the only gene whose overexpression significantly correlated (false discovery rate (FDR) <0.01) with increasing dose for six of the nine compounds, including AA, CdCl\(_2\), CsA, cisplatin, gentamicin, and FK-506 (Figure 2C). There was no significant increase in HO-1 mRNA expression in response to ochratoxin A, tobramycin, doxorubicin, and the nontoxic compound carboplatin. In addition to HO-1, some apoptotic genes such as GADD45A and PMAIP1, were also upregulated in five of the nine compounds as a consequence of a late toxic effect, indicating decreased cell viability (Figure 2C, Supplemental Figure 1). HO-1 protein levels were significantly increased in a dose-dependent manner following exposure to cisplatin, CsA, CdCl\(_2\), AA, gentamicin, and FK-506 for 24 h (Figure 3A), whereas the highest concentration of some compounds resulted in a temporal response of HO-1 as early as 3 h (Supplemental Figure 2A). HO-1 increase was not directly correlated to an increase in production of ROS, showing that it can also detect compounds whose mechanism of toxicity does not involve oxidative stress (Figure 3B). HO-1 mRNA levels were also found to be upregulated more than 10-fold in human proximal renal tubular epithelial cells purchased from human proximal tubular epithelial cells (HPTECs) demonstrate a well-defined differentiated phenotype resembling human proximal tubule kidney cells. (A) Immunohistochemical staining (green) of a representative cell monolayer, seeded on glass slides, shows expression of cytokeratin 18, zonula occludens-1, N-cadherin and E-cadherin proteins (Original magnification, ×40). DAPI was used to counterstain nuclei and is merged with indicated immunofluorescence staining. (B) Semiquantitative PCR gel for proximal tubule-specific genes such as kidney-specific cadherin (356 bp), megalin (296 bp), aquaporin-1 (365 bp), MRP2 (356 bp), MDR1 (251 bp), organic cation transporter 2 (217 bp). Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control (GAPDH, 197 bp). PCR was performed on RNA isolated from HPTECs grown on 12-well plates in two independent experiments cultured up to 10 d and four different passages. RNA from HK2 cells and human kidney were used as comparators. (C) Cells develop a transepithelial electrical resistance (TEER) when cultured on transwell-24 support with an initial density of 25,000 cells/filter. TEER increases to a maximum of 55.07±2.72 V cm\(^2\) in 7 d. (D) Cumulative uptake of \([14C]\)-sucrose via the apical (A) to basolateral (B) or B to A directions was measured after 7, 15, 30, and 60 min. Similar B–A sucrose flux was observed in cells grown on transwell filters and well plate. (E) Rhodamine 123 (Rh123), a fluorescent dye, was used to measure MDR1 activity. The significant decrease in Rh123 fluorescence was determined after incubation with 0.5 \( \mu \)g/ml for 2 h by flow cytometry over a period of 60 min. (F) Cells show dose and time-dependent uptake of a fluorescent glucose substrate (2-NBDG) and inhibition assays suggest activity of Na\(^+\)-dependent glucose transport (SGLT inhibition with phlorizin) as well as Na\(^+\)-independent (GLUT inhibition with cytochalasin B). (G) Effect of cadmium chloride on the \( \gamma \)-glutamyl transferase (GGT) activity and glutathione (GSH) levels in HPTECs. (H) Activity and functionality of mitochondria in HPTECs is shown after perturbation with carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (decreases MMP without induction of ROS), and oligomycin A (induces ROS without loss of MMP). Data corresponds to the mean±SEM from three independent experiments performed in triplicate (*\( P < 0.05 \) compared with control).
Figure 2. HMOX1 differential expression is positively correlated with doses across the highest number of compounds. High throughput gene expression profiling based on the measurement of 1000 genes was performed in human proximal tubular epithelial cells (HPTECs) exposed to a discovery panel of 10 compounds in six different concentrations for 3, 6, 12, and 24 h. (A) For each time point, we calculated the Spearman’s correlation between the six doses and the fold change in mRNA for each gene. A representative example is shown for HMOX1 and cisplatin. The sum of square of the four correlation values is compared with the distribution of values with random data to yield a P value for each pair of gene and compound. Results are shown in a heat map. (B) Based on a cutoff of false discovery rate of 0.05, we ordered genes based on the number of compounds for which gene expression is significantly correlated with dose. HMOX1 is identified as the top gene showing a dose-dependent correlation in six of the nine toxic compounds. Color intensity reflects the average P value for significantly correlated toxicants (the darker, the more significant). (C) Dose and time dependent fold change of
two different sources (LONZA and ATCC) (Supplemental Figure 2B). Incubation of conventionally used immortalized human kidney cell line (HK-2) with similar concentrations of cisplatin, CdCl₂, and AA also showed an increase of HO-1 protein levels; however, gentamicin failed to induce an upregulation of HO-1, and carboplatin (nontoxic control) increased HO-1 concentrations, representing a false positive result (Supplemental Figure 2C).

### Translatability of HO-1 as a Biomarker across Species and Platforms

The relevance of HO-1 induction in in vivo models of kidney toxicity was assessed computationally by mining two large toxicogenomic databases for HO-1 expression following kidney tubular toxicity. The National Toxicology Program’s DrugMatrix as well as the National Institute of Biomedical Innovation’s Toxicogenomics Project-Genomics Assisted Toxicity Evaluation System (TG-GATES) are the two largest toxicogenomics databases and analysis tools that contain in vivo multi-organ rat toxicogenomic data for more than 700 chemicals that are integrated with histopathology and clinical chemistry results from the same animals. As expected, Havcr1 (Kim-1) increase (approximately 47-fold, DrugMatrix $P=2.14E-29$, TG-GATES $P=2.12E-11$) was strongly associated with kidney tubular necrosis in both the DrugMatrix and TG-GATES kidney datasets (Figure 4A, Supplemental Material). Hmox1 was present in both the databases and was upregulated (approximately 2-fold, DrugMatrix $P=3.11E-11$, TG-GATES $P=3.53E-3$) with kidney tubular necrosis and kidney tubular regeneration (Figure 4A, Supplemental Material). Furthermore, Hmox1 expression in both the DrugMatrix and TG-GATES dataset was positively correlated (using linear regression) with expression of a number of transcriptionally inducible biomarkers described in the literature as potential biomarkers of preclinical kidney toxicity (Table 1).

Translatability of HO-1 increase in cells from 2D systems to three-dimensional (3D) systems was assessed by using ex vivo 3D modular microphysiological system (MPS) with human gene expression (z-scored for each gene) for the top four genes of across all 10 compounds. Compounds are ordered for each gene based on the $P$ value of the correlation. A black line separates the compounds with significant correlations from the others, while carboplatin is shown on the right as it serves as a nontoxic control. In addition to HMOX1, an early stress response protein, genes associated with growth arrest and DNA damage (GADD45A), transcriptional regulation of TNF (ZFPI36) and apoptosis (PMAIP1) were found to be significantly upregulated in five of nine compounds. Gene expression changes were calculated as mean compared with 0.1% DMSO controls ($n=4$).
Kidney proximal tubule derived epithelial cells (Figure 4B). HPTECs self-assemble and recapitulate an in vivo structure and function within the microfluidic chips. Under normal conditions, HPTECs in chips show little to no expression of biomarkers, KIM-1 and HO-1, reflecting absence of injury. Consistent with the results obtained using a 2D system (Figure 3) an extremely robust induction of HO-1 was observed in comparison to a modest increase in KIM-1 after exposure of 25 μM cadmium chloride for 48 h (Figure 4B). Plasma and urinary levels of HO-1 have been shown to be a biomarker for AKI in humans and here we present evidence that HO-1 expression was significantly upregulated in primary HPTECs, as well as in rat kidneys and the 3D human kidney-on-a-chip system following tubular toxicity, thereby extending the relevance of HO-1 as a translational biomarker. In comparison, biomarkers like KIM-1 that have very high sensitivity and specificity to detect kidney toxicity in rodents do not show a consistent upregulation following injury to the human primary proximal tubular epithelial cells (Figure 4B, Supplemental Figure 3).

Potential of HO-1 to Predict Kidney Toxicity In Vitro

In order to further evaluate the robustness and sensitivity of HO-1, we tested an additional validation panel (Supplemental Table 1) of 39 well characterized mechanistically distinct compounds that included nontoxic compounds as well as known human kidney toxicants, acting either by direct proximal tubule toxicity or via secondary mechanisms, such as crystal formation in the tubules. All compounds were analyzed for their ability to significantly alter: the number of total cells; the concentration of ATP in cells; the number of dead cells; and the HO-1 concentration in cells. Plotting the maximal significant deregulation compared with control that could be observed at any given concentration of a drug, we calculated the area under the curve receiver-operator characteristic curve (AUC-ROC) for each of the four assays. Including all nontoxic compounds and compounds directly toxic to the proximal tubule, HO-1 was associated with a similar but slightly higher AUC-ROC (0.89) compared with the three other assays: cell number (0.88), cell viability (0.78) and dead cells (0.86) (Figure 5, A and B). This held true, irrespective of whether nephrotoxins following secondary mechanisms of toxicity were included in the analyses or not.

Figure 4. Increase of HO-1 expression in rats and 3D human kidney microfluidic systems following renal injury. (A) Normalized expression intensity of HMOX1 and HAVCR1 in samples positive (+) for tubular necrosis is higher than samples negative (−) for tubule necrosis in the in vivo toxicogenomic databases (DrugMatrix and Toxicogenomics Project-Genomics Assisted Toxicity Evaluation System (TG-GATES)). Each data point represents intensity for a given sample. The bounding box extends from the first to third quartiles, with the central bar indicating the median intensity. Whiskers extend from the ends of the box to the outermost data point that falls within the third quartile+1.5×(interquartile range) and first quartile−1.5×(interquartile range), or to the end of the range. Data points are jittered. (B) Schematic diagram depicting concept of human kidney-on-a-chip. Human proximal tubule epithelial cells (HPTECs) form a confluent tubule in the chip as depicted by the phase contrast of cells and DAPI fluorescent imaging of nuclei. Exposure of HPTECs in the chips with 25 μM CdCl₂ for 48 h resulted in an upregulation of HO-1 depicted by the FITC fluorescent stain. Control devices showed minimal expression of HO-1. KIM-1 expression, absent in untreated devices, marginally increased in response to cadmium chloride in two of four devices.
that performed best, we computed the IC25 (concentration that either cell number or the amount of dead cells (Figure 5C). This could be increased from 75% to 79% when combined with ROC=0.83). The sensitivity of HO-1 as a single biomarker integrating toxicants with secondary mechanisms (AUC-12) tubule toxic compounds (AUC-ROC=0.92) as well as after in- performed the other combinations when examining proximal assays (Figure 5C). Furthermore, HO-1 plus cell number out- performed the others when examining proximal tubule toxic compounds (AUC-ROC=0.92) as well as after in- tegrating toxicants with secondary mechanisms (AUC-ROC=0.83). The sensitivity of HO-1 as a single biomarker could be increased from 75% to 79% when combined with either cell number or the amount of dead cells (Figure 5C).

To also include the dose-response relationship for the assays that performed best, we computed the IC25 (concentration that reduces the number of cells by 25%), and used the HO-1 fold-change data to compute C(HO-1) (concentration at which HO-1 expression was 2 SD away from baseline in the log domain). Normalized viability and HO-1 fold-change curves and com- puted IC25/C(HO-1) values for all compounds from the valida- tion panel are shown in Supplemental Figure 4. Grouping of compounds in their response categories (Figure 5D) generally recapitulated the sensitivity and specificity obtained with the highest deregulation approach: 100% of nontoxic and 100% of secondary toxic compounds were −TOX/-HO-1, 80% of prox- imal tubule toxic compounds were either −TOX/+HO-1 or +TOX/+HO-1, demonstrating that HO-1 is even more sensitive when used in a dose-response manner. Additionally, for nearly all of the +TOX/+HO-1 compounds the C(HO-1) was at least an order of magnitude lower than the IC25 (Figure 5E, Supplemental Figure 4), suggesting that toxicity-related changes in HO-1 expression occurred at a concentration be- low that at which cytotoxic effects can be detected. This finding strongly supports the use of HO-1 as a suitable in vitro biomarker for prediction of kidney toxicity.

DISCUSSION

One of the major challenges in developing safe and effective agents is the accurate prediction of human toxicity for new drug

Table 1. Correlation (R) between normalized intensity of genes across all probe sets exhibiting significant coexpression with HMOX1, for DrugMatrix and TG-GATES datasets

<table>
<thead>
<tr>
<th>Gene Symbol</th>
<th>DrugMatrix</th>
<th></th>
<th></th>
<th></th>
<th>TG-GATES</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Correlation (R)</td>
<td>Significance (P Value)</td>
<td>Correlation (R)</td>
<td>Significance (P Value)</td>
<td>Correlation (R)</td>
<td>Significance (P Value)</td>
<td>Correlation (R)</td>
<td>Significance (P Value)</td>
</tr>
<tr>
<td>Tissue inhibitor of metalloproteinase 1 (Timp1)</td>
<td>0.44</td>
<td>6.25E-69</td>
<td>0.28</td>
<td>2.18E-26</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secreted phosphoprotein 1 (Spp1)</td>
<td>0.21</td>
<td>1.48E-16</td>
<td>0.17</td>
<td>4.11E-11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clusterin (Clu)</td>
<td>0.29</td>
<td>7.03E-29</td>
<td>0.12</td>
<td>7.25E-06</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha-2-macroglobulin (A2m)</td>
<td>0.29</td>
<td>5.26E-29</td>
<td>0.09</td>
<td>0.0005</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipocalin (Lcn2)</td>
<td>0.43</td>
<td>1.08E-65</td>
<td>0.25</td>
<td>4.40E-22</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibronogen β (Fgb)</td>
<td>0.42</td>
<td>2.69E-63</td>
<td>0.18</td>
<td>6.33E-12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laminin, gamma 2 (Lamc2)</td>
<td>0.37</td>
<td>2.23E-48</td>
<td>0.25</td>
<td>2.40E-21</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cd44</td>
<td>0.40</td>
<td>4.89E-57</td>
<td>0.16</td>
<td>3.32E-09</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A virus cellular receptor 1 (Havcr1) also called KIM-1</td>
<td>0.49</td>
<td>9.98E-87</td>
<td>0.3</td>
<td>4.98E-30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Figure 5B). The performance of HO-1 as a biomarker was more sensitive (75%) compared with other known assays of cell death/viability (Figure 5B). The predictive performance of HO-1 in combination with cell number (chi-squared P<0.001), number of dead cells (P<0.001), or ATP (P<0.001) significantly improved as compared with individual assays (Figure 5C). Furthermore, HO-1 plus cell number out- performed the other combinations when examining proximal tubule toxic compounds (AUC-ROC=0.92) as well as after in- tegrating toxicants with secondary mechanisms (AUC-ROC=0.83). The sensitivity of HO-1 as a single biomarker could be increased from 75% to 79% when combined with either cell number or the amount of dead cells (Figure 5C).

To also include the dose-response relationship for the assays that performed best, we computed the IC25 (concentration that reduces the number of cells by 25%), and used the HO-1 fold-change data to compute C(HO-1) (concentration at which HO-1 expression was 2 SD away from baseline in the log domain). Normalized viability and HO-1 fold-change curves and com- puted IC25/C(HO-1) values for all compounds from the valida- tion panel are shown in Supplemental Figure 4. Grouping of compounds in their response categories (Figure 5D) generally recapitulated the sensitivity and specificity obtained with the highest deregulation approach: 100% of nontoxic and 100% of secondary toxic compounds were −TOX/-HO-1, 80% of prox- imal tubule toxic compounds were either −TOX/+HO-1 or +TOX/+HO-1, demonstrating that HO-1 is even more sensitive when used in a dose-response manner. Additionally, for nearly all of the +TOX/+HO-1 compounds the C(HO-1) was at least an order of magnitude lower than the IC25 (Figure 5E, Supplemental Figure 4), suggesting that toxicity-related changes in HO-1 expression occurred at a concentration be- low that at which cytotoxic effects can be detected. This finding strongly supports the use of HO-1 as a suitable in vitro biomarker for prediction of kidney toxicity.
candidates and industrial chemicals. An ideal cell culture system for drug screening would incorporate the two most fundamental properties of an in vitro approach: characteristics of the cells with respect to mimicking human physiology; and sensitivity, specificity, and robustness of a biomarker to quantitate toxicity. Although some clinically relevant in vivo kidney injury biomarkers (KIM-1 and NGAL) are expressed in some proximal tubule lines, their translation to cell-based screening assays has not yet been reported. We did not observe KIM-1 upregulation in HPTECs cultured in 2D consistent with a previous study, or even consistently when HPTECs were cultured in the microphysiological 3D kidney system (Figure 4B), highlighting the need for new biomarkers applicable to in vitro as well as in vivo and human studies. We addressed this issue in the current study and report three important advances: (1) HPTECs possess characteristics of differentiated epithelial cells, such as polar architecture, junctional assembly, expression and activity of transporters, ability to synthesize enzymes like glutathione and γ-glutamyl transferase thereby making them desirable to use in in vitro systems. (2) Changes in expression of HO-1 were found to be more sensitive in predicting compound toxicity in HPTECs than currently used assays of cell viability and cell death. In addition, we show that the sensitivity and specificity can be improved even further by combining the readout for HO-1 concentration and the total cell number, measured in the same well. (3) A newly developed HTRF
To measure HO-1 in a 384 (or 1536) well format was developed to allow rapid, simple, accurate and relatively inexpensive high throughput screening for kidney toxicity, amenable to the Tox21 robotic platform for assessment of chemical-induced toxicity.21,22

HO-1 is ubiquitously expressed in unstressed cells at low levels but is highly induced in response to cell injury mediated by oxidative or proinflammatory stress, heavy metals, ischemia and hypoxia.23,24 Its cytoprotective and anti-apoptotic properties are mediated by degradation of the pro-oxidant heme into iron, biliverdin and carbon monoxide via induction of p38 MAPK and PI3K/Akt signal transduction pathways.25 In contrast, pronounced chemical or genetic inhibition of basal HO-1 levels is associated with increased cell death and tissue necrosis in models of Alzheimer’s disease and aging.26,27 These effects have partly been explained by a lowered antioxidative capacity28 and cells being more susceptible to damaging agents during HO-1 inhibition,29 a property that has been used to sensitize cells for cancer therapy.30 Given that deregulation of HO-1 in HPTECs correlated well with the known toxic effects of the tested compounds in humans, changes in cellular HO-1 might indicate a cellular process to protect from further damage. HO-1 has previously been found to be upregulated in the urine of patients with AKI18 or tubulointerstitial damage.31 HO-1 expression was significantly upregulated in rat kidneys following tubular toxicity and in the human kidney-on-a-chip system following CdCl2 exposure (Figure 4). Hence, we demonstrate the translatability of the 2D in vitro approach all the way to rats, MPSs and humans.

Two-dimensional monolayer cell culture for organs has advantages of being adaptable to high throughput applications such as small molecule discovery screening experiments,32 ‘omics’-based biomarker discovery (Figure 2) or pathway-based risk assessment screening.33 However, despite the fact that HO-1 increase was more pronounced and reliable in primary human compared with immortalized kidney cells (Supplemental Figure 2C), the 2D system for kidney suffers from certain limitations. Those include: lack of estimating
toxicity of compounds that require metabolism and bioactivation by the liver, for example compounds such as acetaminophen, an analgesic with nephrotoxicity attributed to its hepatic metabolite N-acetyl-p-benzoquinone imine; lack of apical to basolateral polarity when cultured on a flat surface, which might not allow the uptake of certain antiviral drugs therefore misrepresenting its safety, for example OAT1 and OAT3, expressed at the basolateral membrane of proximal tubular epithelial cells mediating the uptake of antiviral agents tenofovir and acyclovir.34,35 This lack of basolateral uptake of tenofovir may explain why we did not observe toxic effects in this study. Furthermore, the absence of immune or endothelial cells prevents the assessment of the nephrotoxic potential of immunologically active drugs. For example, the induction of pro-inflammatory cytokines via Toll-like receptors36 is linked to the development of amphotericin B-induced nephrotoxicity in patients.37 In our study the effects of amphotericin B on viability and expression of HO-1 in HPTECs was mild even at high doses, possibly because of a missing immune response in the cell culture system. Finally, the absence of flow might impact on the differentiation and function of the cells while preventing shear stress as well as the interactions with circulating molecules. To address some of these limitations the new organs-on-a-chip initiative aims at using microfluidic cell culture devices that contain continuously perfused chambers inhabited by living cells arranged to simulate tissue and organ-level physiology.38 Although these types of in vitro systems are not amenable to high throughput screening, they may contribute additional orthogonal high content information about the mechanisms of kidney injury.

In summary, in this study we have taken a major step forward from the current approach of using immortalized cell lines and cell viability as an endpoint assay. The use of HO-1 as a translatable, sensitive and specific biomarker that is easy to combine with existing cytotoxicity assays, and the ability to measure HO-1 in 384-well plates using the HTRF assay provides an obvious advantage of scalability over other approaches.

**CONCISE METHODS**

**Cells and Compounds**

Primary HPTECs were purchased from Biopredic International (Rennes, France) and were cultured in supplemented DMEM/Hams-F12 with GlutaMAX medium. Human papillomavirus 16 (HPV-16) transformed kidney proximal tubule cells (HK-2) were purchased from ATCC (Manassas, VA) and cultured in keratinocyte serumfree medium. HPTECs were used in passages 3 and 4, HK-2 cells were used in passage 4. The 10 compounds of the discovery panel (Supplemental Table 1) were purchased from Sigma-Aldrich (Saint Louis, MO) and were used in a broad concentration range from 1.5 μM to 20 mM, reflecting their respective toxicity range in vitro. The compound library that was used as a validation panel contained 39 compounds (Supplemental Table 1) and was custom made from Enzo Life Sciences Inc. (Farmingdale, NY). Cells were cultivated for 3 d in 96 or 384-well plates until confluence and then incubated with either a vehicle control (0.5% DMSO) or toxic and nontoxic compounds in multiple concentrations ranging from 0.1 μM to 554 μM for 3, 6, 12 or 24 h using an automatic 384-well pin transfer system or manually. Cell viability based on ATP concentration was measured using the CellTitre Glo Luminescent assay (Promega). KIM-1 protein was measured in cell lysate and supernatant using microsphere-based Luminox xMAP technology, as described previously.16,39

**Live Cell Imaging and Measurement of Oxidative Stress (ROS) and Number of Dead Cells**

Drug-induced changes in cell morphology, mitochondrial membrane potential, induction of oxidative stress and number of dead cells were quantified using live cell high content imaging. Briefly, 3 d after seeding in 384-well plates, HPTECs were co-incubated for 45 min with 0.5 μM Hoechst 33342 (Active Motif, Carlsbad, CA) to stain nuclei, 0.1 μM tetramethylrhodamine methyl ester (Molecular Probes, Eugene, OR) to measure changes in MMP, and 5 μM CellROX green reagent (Molecular Probes) to detect ROS. After washing off the fluorescent dyes, cells were incubated with 0.2 μM TOTO-3 iodine (Molecular Probes) to stain cells with impaired plasma membrane (dead cells), and treated with the compounds included in both the discovery panel (six concentrations; 1.5 μM to 20 mM) and the validation panel (six concentrations; 0.1 μM to 1000 μM), as well as mitochondrial toxicants (carbonyl cyanide m-chlorophenyl hydrazone, oligomycin A) and live cell images were taken at 3, 6, 12 and 24 h. Experiments were performed in four biologic replicates with duplicate wells on each plate.

**Gene Expression Profiling Using L1000 Platform**

HPTECs cultured in 96-well plates were treated with the 10 toxic and nontoxic compounds in the discovery panel (Supplemental Table 1) in six concentrations (1.6 μM to 20 mM) for 3, 6, 12 and 24 h, and lysed with 100 μl of Tely buffer (Qiagen). Cell lysates were added to the well of a TurboCapture 384 plate to perform mRNA isolation and cDNA synthesis in the same well (TurboCapture 384 mRNA kit; Qiagen). High throughput gene expression analysis is based on the measurement of about 1000 transcripts as described previously.40 Replicates were averaged and values were z-scored across all data. For each pair of gene and drug, Spearman’s correlation Rho1, . . . , Rho6 between the gene expression and the six doses across all four time points (t1, . . . , t4) was calculated. The sum of squares of correlation |Rho|2=∑|Rho|2 for i=1, . . . , 4 if Rhoi>0 was compared with values of |Rho|2 obtained from the correlation of six random values. The comparison with 5,000,000 random values of |Rho|2 yields an empirical P value. A FDR value was used using the Benjamini and Hochberg procedure and gene expression was considered to be significantly positively correlated with drug if FDR<0.01.

**Structural Characterization and HO-1 Measurement by Immunofluorescence Staining**

Primary antibodies used were mouse anti-zonula occludens-1 (Invitrogen), mouse anti-N-cadherin (BD Transduction), mouse anti-Ck18 (CK18; Abcam, Inc., Cambridge, MA), rat anti-E-cadherin (Abcam, Inc.), and mouse anti-HO-1 (BD Transduction). Donkey anti-rat FITC-conjugated antibodies were obtained from Jackson ImmunoResearch, and Alexa Fluor 488 donkey anti-mouse was from Invitrogen. HPTECs were grown on 8-well glass chamber slides
or 384-well plates, fixed in 4% paraformaldehyde or methanol/acetone (1:1), permeabilized with 0.1% Triton X-100, blocked with 5% donkey serum and incubated with respective primary antibody overnight at 4°C. Four replicates were conducted as two replicates on each of two separate days.

Quantification of HO-1 levels and the total number of cells was performed in 384-well plates using immunofluorescence after incubation with eight concentrations (0.1 μM to 554 μM) of each of the 39 compounds included in the validation panel for 24 h. Images (10×, four areas per well) were segmented and quantified using MetaExpress 2.0 (Molecular Devices). The cell scoring module was used to count individual cells (total cells readout) and quantify the level of HO-1 in each cell (% positive cells readout). The readouts for the eight negative vehicle control wells on each 384-well plate were averaged to obtain per-plate baseline values for cell count and percentage of HO-1-positive cells. All noncontrol readouts were divided by the appropriate baseline values to obtain normalized values for cell viability (based on cell number) and fold change in HO-1 expression.

HO-1 Measurement by ELISA and HTRF

ELISA
HPTECs or HK-2 cells were lysed in RIPA buffer and the amount of HO-1 in the cell lysates was quantified by Duoset IC human total HO-1/HMOX1 ELISA kit purchased from R&D Systems Inc. (Minneapolis, MN).

HTRF
The development and optimization process examined best antibody pair analysis, reaction volumes, buffer compositions, cell lysate concentrations and antibody reaction concentrations, and incubation times, with the aim of obtaining a FRET signal following cytotoxicity in HPTECs. A recombinant human HO-1 protein (Abcam, Inc.) was used to generate a standard curve. The best antibody pair showing high Delta F (%) signal between positive and negative lysates was rabbit monoclonal HO-1-antibody (Cell Signaling Technology) labeled with europium cryptate (k) and a d2-conjugated rabbit polyclonal anti HO-1 antibody (Cell Signaling Technology). To detect HO-1 in cell lysates of HPTECs exposed to several compounds, cells were lysed with either 50 μl of Cisbio Lysis Buffer 1 (LB1; Cisbio Bioassays, Bedford, MA) supplemented with 1× protease inhibitor cocktail (96-well) or 10 μl of 4× LB1 (384-well) and stored at −80°C until use. The HTRF emission at 620 nm and 665 nm wavelengths were measured on the Molecular Devices SpectraMax Paradigm using the standard HTRF protocol after 4 h of incubation. Emission at 620 nm is used as internal reference, while emission at 655 nm is proportional to the amount of HO-1. Data are presented as percentages of Delta F [(665/620 ratio−background ratio)/background ratio].

Semiquantitative and Real-Time PCR
Total RNA was isolated, transcribed into cDNA and quantitative or semiquantitative PCR was performed using primers for specific genes listed in Supplemental Table 2.

Transport Activity and Enzymatic Assays
HPTECs were seeded onto collagen IV-coated 6.5 mm, 0.4 μM pore size 24-well Transwell inserts (Corning Life Science) at a density of 2.5×10⁴ cells/well. Cells were incubated with either apically or basolaterally applied [¹⁴C]-sucrose at a concentration of 100 nCi/ml for up to 60 min. An aliquot of 50 μl was removed from the apical and basolateral chamber after 7, 15, 30, and 60 min and the flux was measured using a Beckman scintillation counter. Time and dose-dependent uptake of glucose was measured after incubation of cells with 100, 200, or 500 μM of the fluorescent substrate 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) over the course of 120 min in 96-well plates. Competitive inhibition of SGLT activity was determined in transwell plates after incubation with 250 μM 2-NBDG for 1 h in the presence or absence of 1000 μM phlorizin (SGLT inhibitor) in Na+ and Na+ free buffers. Inhibition of Na+-independent, facilitative transporter activity (GLUT) was shown after pretreatment of HPTECs for 10 min with 50 mM cytochalasin B (SGLT inhibitor) followed by 1 h incubation with 250 μM 2-NBDG in Na+ and Na+ free buffers. The fluorescence intensity of 2-NBDG was measured at excitation and emission wavelengths of 485 nm and 528 nm, respectively, using a Synergy 1H microplate reader (BioTek Instruments, Inc.). Eflux of rhodamine 123 across cell monolayers was measured by incubation of the cells with 0.5 μg/ml substrate for 2 h. Cells were trypsinized, and incubated in rhodamine free media for 0, 7, 15, 30 and 60 min. Rhodamine fluorescence intensity was quantified at 520nm using a flow cytometer (BD Biosciences). Experiments were done in triplicate and were repeated three times. Mean fluorescence intensity was calculated using FlowJo software and plotted. γ-Glutamyl transferase activity was determined by a colorimetric assay from Biovision (Milpitas, CA) in cells treated with 25 or 50 μM CdCl₂ for 24 h and glutathione levels were measured with GSH-Glo assay (Promega) in cells treated with 10 or 50 μM CdCl₂ for 6, 12 and 24 h.

Comparison of HO-1 as Biomarker for Kidney Injury with Known Cell Viability/Cell Death Assays
To compare the predictive performance of HO-1 immunofluorescence staining with established assays of cell toxicity, we first reduced the datasets so that each of the 39 compounds in the validation panel (measured in six to eight different concentrations between 0.1 and 1000 μM) had just one assigned output value per assay. This single value was determined for each of the four assays (HO-1, cell number, ATP concentration, and dead cell number) as the maximal significant deregulation compared with control that could be observed at any given concentration of a drug.

We calculated the AUC-ROC both for proximal tubule toxic drugs only and nephrotoxicants including indirectly acting compounds. To determine for each assay where sensitivity and specificity are maximal, the Youden index was calculated as sensitivity (%) + specificity (%) − 100. Applying this cutoff for each assay, sensitivity was calculated by dividing the number of true positive toxicants by the number of total toxicants in the validation panel. Specificity was calculated by dividing the number of true negative nontoxicants by the number of total nontoxicants in the set. The positive predictive value is defined as the ratio of true positive toxicants to all compounds identified as toxic and the negative predictive value is calculated as the ratio of true negative nontoxicants to all compounds identified as nontoxic. Chi-squared test statistic and corresponding P value were calculated to
describe the goodness of fit of the observed distribution (measured results in the respective assays) to the theoretical one (toxic or non-toxic). Improvement of predictivity via combination of cell death/viability assays with HO-1 was calculated using logistic regression. A combined output was calculated as \( \alpha_{\text{DISP}} + \alpha_{\text{V}} \times \text{value} \times \text{assay 1 (HO-1)} + \alpha_{\text{DISP}} \times \text{value} \times \text{assay 2} \). The final AUC-ROC were calculated using the combined output values both for proximal tubule toxic drugs only and when indirect nephrotoxicants are included.

To include dose-response data into the analysis of HO-1 performance, we used the cell viability data (based on cell number) to compute the IC\(_{25}\) (concentration that kills 25% of the cells), and the HO-1 fold change data to compute \( C_{\text{HO-1}} \) (concentration at which HO-1 induction was 2 SD above or below the baseline in the log domain). To obtain IC\(_{25}\) values from cell viability data, replicates were combined by averaging and the resulting values were fit to four-parameter logistic curves using the L-BFGS-B nonlinear optimization algorithm implemented in Python’s SciPy library. The IC\(_{25}\) was computed by interpolating each fitted viability dose-response curve to find the concentration where the normalized cell viability was 0.75. \( C_{\text{HO-1}} \) values were computed from the HO-1 fold change data by first discarding data points for concentrations above the computed IC\(_{25}\) for each drug (toxicity effects and low IC\(_{25}\) values from cell viability data, replicates were combined by averaging) and then applying the same logistic curve fitting procedure described above on the remaining data. The \( C_{\text{HO-1}} \) was computed by interpolating each fitted HO-1 expression dose-response curve to find the concentration where HO-1 expression exceeded the baseline by plus or minus two times the SD of all negative controls, calculated in the log domain (i.e., the geometric mean multiplied or divided by the geometric SD squared). We flagged each compound as +TOX if it achieved at least 25% toxicity (i.e., the \( E_{\text{max}} \) for the viability dose-response curve was 0.75 or lower) and thus had a defined IC\(_{25}\), or -TOX if it did not in which case we set its IC\(_{25}\) to 1000 \( \mu \text{M} \). Likewise, we used +HO-1 to indicate compounds that showed significant HO-1 induction and thus a defined \( C_{\text{HO-1}} \), and -HO-1 for those that did not in which case we set the \( C_{\text{HO-1}} \) to 1000 \( \mu \text{M} \). The combination of these descriptors defined four response categories: +TOX/+HO-1, -TOX/-HO-1, -TOX/+HO-1 and +TOX/-HO-1.

**Evaluation of HO-1 Expression Using In Vivo Toxicogenomic Databases**

To determine the gene expression profile of HO-1 (Hmox-1) following kidney toxicity *in vivo*, two public toxicogenomics datasets: DrugMatrix (of the National Toxicology Program; https://ntp.niehs.nih.gov/drugmatrix/index.html) and TG-GATES (of the National Institute of Biomedical Innovation; http://toxico.nibio.go.jp/english/index.html) that track kidney gene expression using Affymetrix 230 2.0 microarrays were mined. Prior to the analysis described below, kidney microarray datasets were normalized using the RMA algorithm\(^{2,43}\) implemented in GeneSpring GX 12.6 (Agilent Technologies, Palo Alto, CA). The DrugMatrix and TG-GATES kidney datasets are composed of 1410 and 3728 microarrays, respectively. The DrugMatrix and TG-GATES gene expression data are available through the GEO (Series ID: GSE57811) and ArrayExpress databases (E-MTAB-800), respectively. Association between kidney tubule necrosis and normalized expression of *Hmox1* or *Havcr1* in rat kidney was determined using the Welch *t* test (also known as an unequal variances *t* test) implemented in GeneSpring GX 12.6. Association between *Hmox1* expression and expression of validated kidney toxicity transcriptional biomarkers was performed in Microsoft Excel (Microsoft Corp., Redmond, WA) using the regression statistical function.

**Evaluation of HO-1 Expression in a 3D Human Kidney MPS**

**Cell Isolation and Culture**

Human kidney tissue was obtained from a healthy mass after surgery due to diagnosis of renal carcinoma at the University of Washington Medical Center. The University of Washington Institutional Review Board approved human subjects protocol. Tissue for kidney tubule epithelial cell isolation was stored at 4°C in HBSS buffer containing Pen-Strep and was processed within 24 h as previously described. Primary renal epithelial cells were cultured and grown to confluency in approximately 10 d under normal static conditions.

**Cell Seeding in Nortis Device**

The kidney tubule MPS consists of a tubule embedded in a collagen I matrix. Physical dimensions of the tubule are a length of approximately 6 mm, with an internal diameter of 120 \( \mu \text{M} \) and volume of 70 nl. Each tubule contains approximately 5000 primary proximal tubular epithelial cells. The proximal tubular epithelial cells form a patent confluent tubule that is self-assembling with tight junctions and expression of epithelial markers, including markers of polarization (Weber et al., manuscript in preparation). The Nortis MPS devices were first filled with extracellular matrix of rat tail collagen type I (Ibidi Inc., Verona, WI) at 6 mg/ml at 4°C. The devices were left at 4°C for 30 min and then room temperature overnight. To seed the MPS devices, 3–4 \( \mu \text{l} \) of cell suspension was injected into the lumen of each device. Cells were allowed to recover from trypsin digestion and adhere for 24 h before initiating flow at 0.5 \( \mu \text{l}/\text{min} \). The integrity of the tubule cell structure was assessed grossly by light microscopy on a weekly basis and viability at 4 wks was determined using a LIVE/DEAD Viability/Cytotoxicity kit (Invitrogen, Carlsbad, CA).

**Assessment of CdCl₂-Induced Nephrotoxicity**

MPS devices with approximately 100% tubule confluence after 14+ d in culture were used. Cadmium chloride (Sigma-Aldrich) was flowed through the devices at a final concentration of 25 \( \mu \text{M} \) CdCl₂ while control devices were flowed with normal DMEM-F12 media (0 \( \mu \text{M} \) CdCl₂) for 48 h. At the termination of the experiment, HPTECs in Nortis devices were fixed, permeabilized, blocked and immunofluorescence staining for HO-1 and KIM-1 was performed using respective primary and secondary antibodies: HO-1 (rabbit 1:100; Abcam, Inc.) and KIM-1 (mouse 1:100; R&D Systems, Minneapolis, MN) and goat anti-rabbit or goat anti-mouse (1:1000; Abcam, Inc.) secondary antibodies. Fluorescence images were acquired on Nikon Eclipse Ti-S.

**Statistics**

Unless otherwise indicated, data are presented as mean ± SEM. Statistical difference (*P* < 0.05) as calculated by Student’s *t* test. Multiple group comparison was conducted by ANOVA followed by Dunnett’s *post hoc* test. *P* < 0.05 was considered significant and represented by *
ACKNOWLEDGMENTS

M. Adler was supported by a Colgate Palmolive Postdoctoral Fellowship Award through the Society of Toxicology and M. Hafner was supported by the Swiss National Science Foundation (P300P3_147876).

This work in the Vaida laboratory was supported by an Innovation in Regulatory Science Award from Burroughs Wellcome Fund, Regulatory Science Ignition Award from Harvard Program in Therapeutic Sciences at Harvard Medical School, a pilot project grant from the Harvard-NIEHS Center for Environmental Health (P30ES000002), National Institutes of Health (NIH) grant U13-TR000504 and resources made available through the NIH LINCS grant U54-HG006097.

The authors appreciate the support of ICCB-Longwood facility at Harvard Medical School in training M. Adler and S. Ramm for compound library preparation and high throughput HO-1 cell staining.

The authors also appreciate the support of Harvard Catalyst, The Harvard Clinical and Translational Science Centre for statistical advice.

DISCLOSURES

None.

REFERENCES


This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2015010060/-/DCSupplemental.